StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Puma Biotechnology (PBYI) Nerlynx Has More Competition as Seattle Genetics Acquires Tucatinib - Stifel
January 31, 2018 12:13 PM
Stifel analyst Alex Schwartz weighed in on Puma Biotechnology (NASDAQ: PBYI) after Seattle Genetics (NASDAQ: SGEN) acquired Cascadian Therapeutics, whos ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
FDA
Next Articles
Seattle Genetics (SGEN) Prices 11.54M Share Common Offering at $52/Sh
February 1, 2018 6:43 AM
Puma Biotech (PBYI) Reports Publication of Results from Phase II SUMMIT 'Basket' Trial Evaluating Neratinib in HER2 and HER3 Mutant
January 31, 2018 1:21 PM